ARGATROBAN IN SODIUM CHLORIDE
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, platelet activation, and clot formation.
| Metabolism | Primarily hepatic via CYP3A4/5; metabolites (unchanged, hydroxylated, and carboxylated) are excreted mainly in bile. |
| Excretion | Primarily hepatic (biliary/fecal); approximately 65% excreted in feces and 22% in urine (unchanged drug minimal). Renal elimination accounts for 16% as unchanged drug. Dosage adjustment required for hepatic impairment; not significantly affected by renal impairment. |
| Half-life | Terminal elimination half-life: 39–51 minutes (mean ~45 min) following intravenous infusion. In hepatic impairment, half-life is prolonged up to 3-fold. Short half-life allows rapid offset of anticoagulation if needed. |
| Protein binding | 54% bound to human serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution: 0.2–0.4 L/kg (approx. 174 mL/kg). Indicates distribution primarily in extracellular fluid. |
| Bioavailability | Intravenous: 100% (administered as an IV infusion only; not available for other routes). |
| Onset of Action | Intravenous: Immediate, with anticoagulant effect reaching steady state within 1–3 hours with continuous infusion. |
| Duration of Action | Intravenous: Anticoagulant effect persists for 1–2 hours after discontinuation, with aPTT returning to baseline within 2–4 hours. Dose-dependent; monitored via aPTT. |
| Molecular Weight | 526.66 |
Initial dose: 2 mcg/kg/min IV continuous infusion; maintenance: titrate to aPTT 1.5-3 times baseline, not to exceed 10 mcg/kg/min.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; caution in dialysis patients as drug is removed by hemodialysis. |
| Liver impairment | For Child-Pugh class A, B, or C: initial dose 0.5 mcg/kg/min IV continuous infusion with frequent aPTT monitoring. |
| Pediatric use | Safety and effectiveness not established; limited data: initial dose 0.75 mcg/kg/min IV; titrate to aPTT 1.5-3 times baseline, max 2 mcg/kg/min. |
| Geriatric use | No specific dose adjustment; increased risk of bleeding due to age-related changes; monitor aPTT closely and use lower initial doses if frail. |
| 1st trimester | Argatroban is a direct thrombin inhibitor; there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed and potential benefit justifies potential risk to the fetus. Animal studies have shown no teratogenic effects at clinically relevant doses. |
| 2nd trimester | Same as first trimester. Limited data; theoretical risk of bleeding or adverse effects on fetal development. Use with caution only if clearly indicated. |
| 3rd trimester | Argatroban crosses the placenta. Risk of maternal and fetal hemorrhage, especially during labor and delivery. Use only if anticoagulation is essential and alternative agents are not appropriate. Monitor for signs of bleeding. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Yes, argatroban crosses the placenta in humans. Fetal plasma concentrations are approximately 20-30% of maternal concentrations based on limited data. |
| Breastfeeding | No data on presence in human milk; because many drugs are excreted in human milk and potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother. |
| Lactation Rating | L3 (Limited data - possibly compatible) |
| Teratogenic Risk | Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: increased risk of maternal hemorrhage; fetal risk minimal. |
| Fetal Monitoring | Monitor aPTT (target 1.5-3 times baseline), platelet count (risk of HIT), signs of bleeding (maternal/fetal), and fetal heart rate if applicable. |
| Fertility Effects | No known effects on fertility in animal studies. |
■ FDA Black Box Warning
WARNING: Risk of bleeding. Argatroban can cause major bleeding, including intracranial hemorrhage, especially in patients with hepatic impairment or other risk factors for bleeding. Monitor for signs of bleeding and adjust dose accordingly.
| Common Effects | fluid replacement |
| Serious Effects |
Major bleedingHistory of hypersensitivity to argatrobanSevere hepatic impairment (Child-Pugh >6 or total bilirubin >3 mg/dL with ALT/AST >5x ULN)
| Precautions | Bleeding risk: Increased risk of hemorrhage, especially in patients with hepatic dysfunction, severe hypertension, or concomitant antithrombotic therapy, Hepatic impairment: Dose reduction required; may lead to prolonged anticoagulation, Renal impairment: Caution in severe renal impairment; no dose adjustment recommended but monitoring advised, Pregnancy: Limited data, use only if clearly needed, Lactation: Not recommended, Pediatric use: Safety and efficacy not established, Elderly: Increased sensitivity; monitor closely |
| Food/Dietary | No specific food interactions. Maintain consistent intake of vitamin K-rich foods if on warfarin transition. |
| Clinical Pearls | Argatroban is a direct thrombin inhibitor used for heparin-induced thrombocytopenia (HIT). Monitor aPTT closely, targeting 1.5-3 times baseline. Dose adjustment required in hepatic impairment. Do not use intramuscularly due to bleeding risk. Antidote not available; half-life ~50 minutes. |
| Patient Advice | Report any unusual bleeding or bruising immediately. · Avoid aspirin, NSAIDs, and other blood thinners unless prescribed by your doctor. · You will have regular blood tests to monitor clotting time. · Notify all healthcare providers that you are taking this medication. · Do not stop or change dose without consulting your doctor. |
Loading safety data…